IT1254359B - Composizioni farmaceutiche contenenti il-6 - Google Patents

Composizioni farmaceutiche contenenti il-6

Info

Publication number
IT1254359B
IT1254359B ITRM920349A ITRM920349A IT1254359B IT 1254359 B IT1254359 B IT 1254359B IT RM920349 A ITRM920349 A IT RM920349A IT RM920349 A ITRM920349 A IT RM920349A IT 1254359 B IT1254359 B IT 1254359B
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
compositions containing
compositions
recombined
trehalose
Prior art date
Application number
ITRM920349A
Other languages
English (en)
Inventor
Fabrizio Samaritani
Original Assignee
Serono Cesare Ist Ricerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Cesare Ist Ricerca filed Critical Serono Cesare Ist Ricerca
Publication of ITRM920349A0 publication Critical patent/ITRM920349A0/it
Priority to ITRM920349A priority Critical patent/IT1254359B/it
Priority to ES93909917T priority patent/ES2105257T3/es
Priority to PCT/EP1993/001120 priority patent/WO1993023065A1/en
Priority to CA002117761A priority patent/CA2117761C/en
Priority to DK93909917.2T priority patent/DK0641216T3/da
Priority to EP93909917A priority patent/EP0641216B1/en
Priority to AU40653/93A priority patent/AU676833B2/en
Priority to JP51984193A priority patent/JP3714951B2/ja
Priority to AT93909917T priority patent/ATE157256T1/de
Priority to DE69313444T priority patent/DE69313444T2/de
Priority to US08/335,874 priority patent/US5635176A/en
Publication of ITRM920349A1 publication Critical patent/ITRM920349A1/it
Application granted granted Critical
Publication of IT1254359B publication Critical patent/IT1254359B/it
Priority to GR970402352T priority patent/GR3024708T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composizioni farmaceutiche di Interleuchina-6 (IL-6) stabilizzate con zuccheri non riducenti, come saccarosio e trealosio. Le composizioni possono anche contenere un amminoacido o albumina umana come eccipiente.La formulazione è particolarmente adatta per la stabilizzazione di IL-6 ricombinate, come polvere secca liofilizzata.
ITRM920349A 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6 IT1254359B (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6
AU40653/93A AU676833B2 (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing IL-6
AT93909917T ATE157256T1 (de) 1992-05-11 1993-05-07 Il-6 enthaltende pharmazeutische zusammensetzungen stabilisiert mit einem nicht- reduzierenden zucker
CA002117761A CA2117761C (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing il-6
DK93909917.2T DK0641216T3 (da) 1992-05-11 1993-05-07 Farmaceutisk præparat indeholdende IL-6
EP93909917A EP0641216B1 (en) 1992-05-11 1993-05-07 PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6 stabilized with a non-reducing sugar
ES93909917T ES2105257T3 (es) 1992-05-11 1993-05-07 Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor.
JP51984193A JP3714951B2 (ja) 1992-05-11 1993-05-07 Ｉｌ−６含有薬剤組成物
PCT/EP1993/001120 WO1993023065A1 (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing il-6
DE69313444T DE69313444T2 (de) 1992-05-11 1993-05-07 IL-6 ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN stabilisiert mit einem nicht-reduzierenden Zucker
US08/335,874 US5635176A (en) 1992-05-11 1993-05-07 Pharmaceutical compositions containing IL-6
GR970402352T GR3024708T3 (en) 1992-05-11 1997-09-11 Pharmaceutical compositions containing il-6.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6

Publications (3)

Publication Number Publication Date
ITRM920349A0 ITRM920349A0 (it) 1992-05-11
ITRM920349A1 ITRM920349A1 (it) 1993-11-11
IT1254359B true IT1254359B (it) 1995-09-14

Family

ID=11400994

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6

Country Status (12)

Country Link
US (1) US5635176A (it)
EP (1) EP0641216B1 (it)
JP (1) JP3714951B2 (it)
AT (1) ATE157256T1 (it)
AU (1) AU676833B2 (it)
CA (1) CA2117761C (it)
DE (1) DE69313444T2 (it)
DK (1) DK0641216T3 (it)
ES (1) ES2105257T3 (it)
GR (1) GR3024708T3 (it)
IT (1) IT1254359B (it)
WO (1) WO1993023065A1 (it)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433760B1 (en) 1999-01-14 2002-08-13 University Of Central Florida Head mounted display with eyetracking capability
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002053136A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0645452A1 (en) * 1985-10-14 1995-03-29 Yeda Research And Development Co. Ltd. Human interferon-beta 2A and interfeon-beta 2B, vectors containing genes coding for said interferons, cell lines producing same and use of said interferons as pharmaceuticals
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
JPH0327320A (ja) * 1989-06-26 1991-02-05 Ajinomoto Co Inc ヒトｂ細胞分化因子医薬組成物
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
WO1993006840A1 (en) * 1991-10-09 1993-04-15 Toray Industries, Inc. Medicine for preventing and treating bleeding tendency
JP3027320U (ja) 1996-01-27 1996-08-09 三千男 高橋 野球グラブの装着補強具

Also Published As

Publication number Publication date
WO1993023065A1 (en) 1993-11-25
AU676833B2 (en) 1997-03-27
AU4065393A (en) 1993-12-13
EP0641216A1 (en) 1995-03-08
DE69313444D1 (de) 1997-10-02
EP0641216B1 (en) 1997-08-27
JPH08502722A (ja) 1996-03-26
DK0641216T3 (da) 1998-01-26
CA2117761C (en) 2005-10-04
ITRM920349A1 (it) 1993-11-11
ATE157256T1 (de) 1997-09-15
US5635176A (en) 1997-06-03
CA2117761A1 (en) 1993-11-25
ITRM920349A0 (it) 1992-05-11
ES2105257T3 (es) 1997-10-16
JP3714951B2 (ja) 2005-11-09
DE69313444T2 (de) 1998-01-02
GR3024708T3 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
IT1254359B (it) Composizioni farmaceutiche contenenti il-6
MXPA03000046A (es) Interleucina-2 estabilizada.
ES2117781T3 (es) Preparaciones farmaceuticas liofilizadas y estables de g-csf.
IT1250075B (it) Composizioni farmaceutiche contenenti gonadotropine.
NO931919L (no) Optisk aktivt 5h-pyrrolo(3,4-b)pyrazinderivat, dets fremstilling samt farmasoeytiske preparater inneholdende derivatet
ATE353665T1 (de) Glp-2 enthaltende formulierungen
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
DK605786D0 (da) Stabiliserede human-vaevsplasminogenaktivator-praeparater
HU9401831D0 (en) Stabilized pharmaceutical formulations comprising growth hormone and asparagine
IT1240314B (it) Formulazioni acquose stabilizzate di piccoli peptidi.
DK0697887T3 (da) Stabile flydende gamma-interferonholdige præparater
EP0370481A3 (de) Pharmazeutische Präparate zur verbesserten Resorption antibakterieller Verbindungen
DE69420872D1 (de) Hgh enthaltende pharmazeutische zubereitungen
IT1272252B (it) Formulazioni liquide di interferone beta
IL87778A0 (en) Pharmaceutical compositions containing stabilized therapeutically active proteins and their preparation
IL74827A0 (en) Peptides active as gnrh antagonists and pharmaceutical compositions containing them
PH27446A (en) Compound with gastric acid inhibitory effect
ZA787353B (en) Pharmaceutical formulations
UA26898C2 (uk) Стабілізоваhа фармацевтичhа композиція hа осhові рекомбіhаhтhого hеглікозиловаhого іhтерлейкіhу il-2 людиhи у відhовлеhому вигляді, спосіб її одержаhhя і спосіб стабілізації даhої фармацевтичhої композиції
YU44292A (sh) Superaktivni analozi faktora oslobadjanja hormona rasta
GB2021581A (en) Stabilisation of PGl2 derivatives
IT8548799A0 (it) Composizione erbicida e procedimento per la preparazione del suo ingrediente attivo
DE3573724D1 (en) Use of 1,8,9-triacetoxy-anthracene as the active ingredient in the preparation of an antitumoral pharmaceutical compound
ITMI922332A1 (it) Composizioni farmaceutiche per la somministrazione di paratormone, suoi frammenti biologicamente attivi o peptidi correlati per via rettale.